All In Biotech

Drugs by condition

Drugs approved for influenza

Brand-name prescription drugs and biologics whose FDA label lists influenza as an approved use. Matched on the label phrases: "influenza".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

8

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

4

New molecular entities and new biologics

In development

24

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for influenza.

  • Xofluza (Baloxavir Marboxil) · Genentech INC Aug 11, 2022
  • Xofluza (Baloxavir Marboxil) · Genentech INC NovelPriority reviewOct 24, 2018
  • Vigamox (Moxifloxacin Hydrochloride) · Harrow Eye Apr 15, 2003
  • Tamiflu (Oseltamivir Phosphate) · Roche Priority reviewDec 14, 2000
  • Tamiflu (Oseltamivir Phosphate) · Roche NovelPriority reviewOct 27, 1999

All approved drugs for influenza, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 69 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Neuraminidase Inhibitor (1)

  • Relenza Zanamivir · Glaxosmithkline · 1999

Class not listed in FDA's data (7)

  • Xofluza Baloxavir Marboxil · Genentech INC · 2018
  • Tamiflu Oseltamivir Phosphate · Roche · 1999
  • Cefotan Cefotetan Disodium · Pai Holdings Pharm · 1985
  • Xofluza Baloxavir Marboxil · Genentech INC · 2022
  • Vigamox Moxifloxacin Hydrochloride · Harrow Eye · 2003
  • Tamiflu Oseltamivir Phosphate · Roche · 2000
  • Eryped Erythromycin Ethylsuccinate · Carnegie · 1965

Drugs in development for influenza

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)

  • GP681Phase 32 trials

    Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza

  • GP681 SimulantPhase 32 trials

    Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza

  • IIV-HDstandalonePhase 32 trials

    Sanofi · COVID-19 Immunization, Influenza Immunization, Immunization

  • LG Chem · Diphtheria, Tetanus, Pertussis

  • ZSP1273Phase 32 trials

    Guangdong Raynovent Biotech Co., Ltd · Influenza A, Influenza a

  • ADC189Phase 31 trial

    Jiaxing AnDiCon Biotech Co.,Ltd · Influenza Type A, Influenza Type B

  • BK1803Phase 31 trial

    Tanabe Pharma Corporation · Pertussis, Diphtheria, Tetanus

  • BRC-201TG-1000, Pixavir MarboxilPhase 31 trial

    Boryung Biopharma Co., Ltd. · Influenza

  • mRNA-1018-H5Phase 31 trial

    Moderna · Influenza

  • NVXC19EU licensed, standalonePhase 31 trial

    Sanofi · Immunization, Healthy Volunteers, COVID-19 Immunization

  • Flu mRNAGSK6479720A, GSK6498032APhase 22 trials

    GSK · Influenza, Human

  • Fluzone QudrivalentPhase 22 trials

    Sanofi · Healthy Volunteers, Influenza Immunization, Influenza

  • rC19Novavax's adjuvanted recombinant COVID-19Phase 22 trials

    Sanofi · COVID-19 Immunization, Influenza Immunization

  • TRX-100Phase 22 trials

    Traws Pharma, Inc. · Influenza

  • ApomivirFE-L-APO, drug substancePhase 21 trial

    Far East Bio-Tec Co., Ltd · Influenza

  • ARCT-2304Phase 21 trial

    Arcturus Therapeutics, Inc. · Influenza, Human

  • AZD4117Phase 21 trial

    AstraZeneca · Influenza A

  • AZD5315Phase 21 trial

    AstraZeneca · Influenza A

  • DL001ZF2G22B, F2H23HPhase 21 trial

    GSK · Influenza, Human

More on influenza: recruiting trials · published research

Related in infectious disease and vaccines: HIV · Hepatitis B · Hepatitis C · COVID-19 · RSV · Urinary tract infection · Pneumonia · Skin infections · C. difficile infection · Fungal infections

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.